Latest

Managed Markets: Medicare Marketing Confidential

Managed Markets: Medicare Marketing Confidential

The Medicare enrollment period that just concluded differed in one major way from those of years past: Marketers found, both to their delight and chagrin, that the pool of Medicare eligibles now includes many individuals perfectly comfortable with digital communications. Tom Reid shares a few thoughts on what marketers have learned—or, in some cases, should've learned

Teva settles pay-for-delay case for $1.2 billion

Teva reached a settlement with the Federal Trade Commission to resolve an antitrust suit that charged the drugmaker's subsidiary Cephalon with illegally blocking generic competition for narcolepsy drug Provigil.

Five things for pharma marketers to know Thursday, May 28

Five things for pharma marketers to know Thursday, May 28

The FBI is investigating Johnson & Johnson's morcellator; Sanofi purchased another priority review voucher; generic drug prices are falling at a slow rate

Mango Health takes on chronic conditions

Mango Health takes on chronic conditions

The updated app now tracks everyday health metrics including weight, activity and glucose levels.

Three Technologies Driving Sales in Life Sciences

Three Technologies Driving Sales in Life Sciences

Multiple marketing channels offer an effective way to ensure that meaningful relationships can be developed with prospects and when done right can increase revenue by more than 10% while reducing costs by 25%, if not both

Therapeutic Focus: Infectious Diseases

Therapeutic Focus: Infectious Diseases

While advances in the treatment of hep.-C have been well noted, the infectious-diseases space has seen considerably less innovation than many other therapeutic areas. Given the stubbornness of superbugs like MRSA and growing antibiotic resistance, the healthcare industry has finally turned its attention to the category. Rebecca Mayer Knutsen outlines the potential threats and solutions

Express Scripts wants cancer drugs to prove value

Express Scripts wants cancer drugs to prove value

The pharmacy benefits manager wants oncology treatments priced according to how well they treat a specific cancer as opposed to using the current one-price-fits-all approach.

Roche diagnostic unit partnering with drugmaker on companion diagnostic

The test seeks to identify patients with metastatic pancreatic cancer and high levels of hyaluronan.

New bill seeks to spur FDA to form clearer social media rules

New bill seeks to spur FDA to form clearer social media rules

Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.

Five things for pharma marketers to know: Wednesday, May 27

Five things for pharma marketers to know: Wednesday, May 27

Express Scripts seeks to pay more for top-performing cancer drugs; Olympus plans to settle marketing investigation; Novartis is collaborating on a robotic pill

Med-Tech Marketing: Wearables and Beyond

Med-Tech Marketing: Wearables and Beyond

Long considered one of the staid, self-contained areas of the healthcare biz, the device/diagnostics space has enjoyed an injection of energy as the potential for integration with mobile devices has become more obvious. But are these companies set up to work alongside their traditional pharma partners, much less the entrepreneurial-minded start-ups that aim to reinvent the category? Larry Dobrow surveys the opportunities and frustrations

NPs expand right to practice independently

Twenty states now allow nurse practitioners to practice without an MD affiliation.

ASCO preview: What's coming for lung cancer

ASCO preview: What's coming for lung cancer

A horse race between Merck and Bristol-Myers Squibb, and the importance of one biomarker, will be a focus at the American Society of Clinical Oncology's annual meeting.

Court orders Actavis to keep Namenda IR on market

An appeals court affirmed an earlier ruling that Actavis must keep an older formulation of its Alzheimer's drug, Namenda, on the market.

J&J puts global media business up for review

J&J puts global media business up for review

The review does not include North America, the healthcare giant said.

Agency Spotlight



Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters